Yohann Loriot, MD, PhD

Vadim Koshkin, MD

GU Oncology Now

<p>Yohann Loriot, MD, PhD, Gustave Roussy Cancer Institute, and Vadim Koshkin, MD, University of California, San Francisco, summarize the latest data presented on cohort 1 of the THOR study, which compared erdafitinib and chemotherapy in patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations.<p><a href="https://guoncologynow.com/category/asco-2023" target="_blank" rel="noopener">View more ASCO 2023 videos</a>.</p></p>


Drs. Loriot, Koshkin on Results From Cohort 1 of the THOR Study

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

Drs. Loriot and Koshkin summarize erdafitinib versus chemotherapy in patients with advanced or metastatic UC with select FGFR alterations.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe